Perceptive Advisors LLC Invests $2.02 Million in Corcept Therapeutics Incorporated $CORT

02 Aug 2026, 10:50 by Danessa Lincoln · The Markets Daily

Perceptive Advisors LLC bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the 1st quarter, HoldingsChannel reports. The fund bought 50,000 shares of the biotechnology company’s stock, valued at approximately $2,016,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CORT. Royal Bank of Canada increased its position in Corcept Therapeutics by 18.9% during the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock worth $1,757,000 after purchasing an additional 2,444 shares during the period. Amundi purchased a new position in shares of Corcept Therapeutics during the 1st quarter worth approximately $450,000. NewEdge Advisors LLC acquired a new stake in shares of Corcept Therapeutics in the 1st quarter valued at approximately $518,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Corcept Therapeutics by 273.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,441 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 1,055 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of Corcept Therapeutics by 795.3% in the second quarter. Marshall Wace LLP now owns 46,200 shares of the biotechnology company’s stock valued at $3,391,000 after buying an additional 41,040 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director David L. Mahoney sold 20,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $84.53, for a total value of $1,690,600.00. Following the sale, the director directly owned 26,147 shares in the company, valued at $2,210,205.91. The trade was a 43.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James N. Wilson sold 10,000 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $83.20, for a total transaction of $832,000.00. Following the completion of the sale, the director directly owned 1,094,543 shares in the company, valued at approximately $91,065,977.60. The trade was a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 300,000 shares of company stock valued at $22,088,050. Company insiders own 20.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective on the stock. in a report on Monday, July 27th. Piper Sandler reissued an “overweight” rating and issued a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday. UBS Group set a $135.00 target price on shares of Corcept Therapeutics in a research report on Thursday, May 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.17.

Check Out Our Latest Stock Analysis on Corcept Therapeutics

Corcept Therapeutics Price Performance

NASDAQ CORT opened at $114.49 on Friday. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $122.21. The company has a market capitalization of $12.38 billion, a P/E ratio of 272.60 and a beta of 0.47. The business has a 50 day moving average price of $84.77 and a 200 day moving average price of $56.78.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.34. The firm had revenue of $256.15 million during the quarter, compared to analysts’ expectations of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.Corcept Therapeutics’s revenue was up 31.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.29 earnings per share. On average, research analysts expect that Corcept Therapeutics Incorporated will post 1.13 earnings per share for the current fiscal year.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

Positive Sentiment: Corcept reported second-quarter earnings of $0.36 per share, well above the $0.02 analyst consensus, while revenue reached $256.15 million versus expectations of $221.15 million. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
Positive Sentiment: Piper Sandler initiated or reiterated an “Overweight” rating, adding to the bullish analyst sentiment surrounding Corcept’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
Positive Sentiment: HC Wainwright sharply raised its Q3 2026 EPS estimate to $0.78 from $0.34 and lifted its full-year 2026 forecast to $2.15 from $0.80. The firm maintained a “Buy” rating and a $165 price target, implying continued confidence in near-term earnings momentum.
Neutral Sentiment: Analyst coverage remains mixed: HC Wainwright’s revised estimates imply strong 2026 earnings growth, but the firm reduced several 2027 quarterly forecasts and lowered FY2027 EPS to $3.95 from $5.38. This suggests expectations for longer-term growth have moderated.
Negative Sentiment: Some investors may be concerned that the stock’s rapid rise has already priced in much of LIFYORLI’s potential. A recent analysis described the drug as likely to become a blockbuster but warned that Corcept’s valuation leaves limited room for disappointment. Corcept Therapeutics: LIFYORLI Is Likely a Blockbuster, But the Valuation Already Knows It

Corcept Therapeutics Profile

(Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.